المؤلفون: Fernandez-Perez MP; Department of Haematology and Medical Oncology, Hospital Universitario Morales Meseguer, IMIB, Murcia, Spain., Perez-Navarro E; Department of Medical Oncology, Instituto de Investigación, Hospital Universitario 12 de Octubre, Madrid, Spain., Alonso-Gordoa T; Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain., Conteduca V; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) 'Dino Amadori' IRCCS, Meldola, Italy., Font A; Department of Medical Oncology, Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (BARGO), Badalona, Spain., Vázquez-Estévez S; Department of Medical Oncology, H. Universitario Lucus Augusti, Lugo, Spain., González-Del-Alba A; Department of Medical Oncology, H.U. Son Espases, Palma de Mallorca, Spain., Wetterskog D; University College London Cancer Institute, Paul O'Gorman Building, London, UK., Antonarakis ES; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Mellado B; Department of Medical Oncology, IDIBAPS, Hospital Clinic, Universidad de Barcelona, Barcelona, Spain., Fernandez-Calvo O; Department of Medical Oncology, Complejo Hospitalario Universitario Ourense, Orense, Spain., Méndez-Vidal MJ; Department of Medical Oncology, Hospital Universitario Reina Sofía (HURS), Maimonides Institute for biomedical research of Córdoba (IMIBIC), Córdoba, Spain., Climent MA; Servicio de Oncología Médica, Instituto Valenciano de Oncología, Valencia, Spain., Duran I; Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain., Gallardo E; Department of Medical Oncology, Servicio de Oncología Médica, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain., Rodriguez Sanchez A; Department of Medical Oncology, Hospital Universitario de León, León, Spain., Santander C; Department of Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain., Sáez MI; Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain., Puente J; Department of Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain., Tudela J; Department of Pathology, Hospital Morales Meseguer, Murcia, Spain., Martínez A; Biobanco de la región de Murcia, IMIB, Nodo 3, Murcia, Spain., López-Andreo MJ; Department of Molecular Biology, SAI-IMIB-Universidad de Murcia, Murcia, Spain., Padilla J; Department of Haematology and Medical Oncology, Hospital Universitario Morales Meseguer, IMIB, Murcia, Spain., Lozano R; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain.; Genitourinary Translational Research Group, Instituto de Investigación Biomédica de Málaga, Málaga, Spain., Hervas D; Data Science Unit, Instituto de Investigación Sanitaria La Fe, Valencia, Spain., Luo J; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., de Giorgi U; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) 'Dino Amadori' IRCCS, Meldola, Italy., Castellano D; Department of Medical Oncology, Instituto de Investigación, Hospital Universitario 12 de Octubre, Madrid, Spain., Attard G; University College London Cancer Institute, Paul O'Gorman Building, London, UK., Grande E; MD Anderson Cancer Center Madrid, Madrid, Spain., Gonzalez-Billalabeitia E; Department of Haematology and Medical Oncology, Hospital Universitario Morales Meseguer, IMIB, Murcia, Spain.; Department of Medical Oncology, Instituto de Investigación, Hospital Universitario 12 de Octubre, Madrid, Spain.; Universidad Católica San Antonio de Murcia-UCAM, Murcia, Spain.

المصدر: The Prostate [Prostate] 2023 Mar; Vol. 83 (4), pp. 376-384. Date of Electronic Publication: 2022 Dec 23.

نوع المنشور: Clinical Trial, Phase II; Journal Article

بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8101368 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0045 (Electronic) Linking ISSN: 02704137 NLM ISO Abbreviation: Prostate Subsets: MEDLINE

مواضيع طبية MeSH: Neoplastic Cells, Circulating*/pathology , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/genetics , Prostatic Neoplasms, Castration-Resistant*/pathology, Humans ; Male ; Biomarkers, Tumor/genetics ; Nitriles/therapeutic use ; Prognosis ; Prostate-Specific Antigen ; Receptors, Androgen/genetics

المؤلفون: de la Morena-Barrio ME; Servicio de Hematología y Oncología Médica, Hospital General Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CIBERER, Avda. Marqués de Los Vélez, s/n, 30008, Murcia, Spain., Bravo-Pérez C; Servicio de Hematología y Oncología Médica, Hospital General Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CIBERER, Avda. Marqués de Los Vélez, s/n, 30008, Murcia, Spain., Miñano A; Servicio de Hematología y Oncología Médica, Hospital General Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CIBERER, Avda. Marqués de Los Vélez, s/n, 30008, Murcia, Spain., de la Morena-Barrio B; Servicio de Hematología y Oncología Médica, Hospital General Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CIBERER, Avda. Marqués de Los Vélez, s/n, 30008, Murcia, Spain., Fernandez-Perez MP; Servicio de Hematología y Oncología Médica, Hospital General Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CIBERER, Avda. Marqués de Los Vélez, s/n, 30008, Murcia, Spain., Bernal E; Servicio de Enfermedades Infecciosas, Hospital Reina Sofía, Murcia, Spain., Gómez-Verdu JM; Servicio de Medicina Interna, Hospital Universitario Morales Meseguer, Murcia, Spain., Herranz MT; Servicio de Medicina Interna, Hospital Universitario Morales Meseguer, Murcia, Spain., Vicente V; Servicio de Hematología y Oncología Médica, Hospital General Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CIBERER, Avda. Marqués de Los Vélez, s/n, 30008, Murcia, Spain., Corral J; Servicio de Hematología y Oncología Médica, Hospital General Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CIBERER, Avda. Marqués de Los Vélez, s/n, 30008, Murcia, Spain. Javier.corral@carm.es., Lozano ML; Servicio de Hematología y Oncología Médica, Hospital General Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CIBERER, Avda. Marqués de Los Vélez, s/n, 30008, Murcia, Spain.

المصدر: Scientific reports [Sci Rep] 2021 Apr 08; Vol. 11 (1), pp. 7792. Date of Electronic Publication: 2021 Apr 08.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

مواضيع طبية MeSH: COVID-19/*diagnosis , Thrombin/*analysis, Adult ; Aged ; Blood Coagulation Tests ; COVID-19/blood ; Disseminated Intravascular Coagulation/blood ; Disseminated Intravascular Coagulation/diagnosis ; Female ; Fibrin Fibrinogen Degradation Products/analysis ; Hospitalization ; Humans ; Male ; Middle Aged ; Prognosis ; SARS-CoV-2/isolation & purification ; Thrombosis/blood ; Thrombosis/diagnosis

المؤلفون: Lozano ML; Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Servicio de Hematología y Oncología Médica, Universidad de Murcia , Murcia, Spain.; Grupo de investigación CB15/00055 del Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII) , Madrid, Spain., Garabet L; Multidisciplinary Laboratory Medicine and Medical Biochemistry, Akershus University Hospital , Lørenskog, Norway.; Center for Laboratory Medicine, Østfold Hospital Trust , Grålum, Norway.; Institute of Clinical Medicine, University of Oslo , Oslo, Norway., Fernandez-Perez MP; Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Servicio de Hematología y Oncología Médica, Universidad de Murcia , Murcia, Spain., De Los Reyes-García AM; Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Servicio de Hematología y Oncología Médica, Universidad de Murcia , Murcia, Spain., Diaz-Lozano P; Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Servicio de Hematología y Oncología Médica, Universidad de Murcia , Murcia, Spain., Garcia-Barbera N; Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Servicio de Hematología y Oncología Médica, Universidad de Murcia , Murcia, Spain., Aguila S; Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Servicio de Hematología y Oncología Médica, Universidad de Murcia , Murcia, Spain., Vicente V; Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Servicio de Hematología y Oncología Médica, Universidad de Murcia , Murcia, Spain.; Grupo de investigación CB15/00055 del Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII) , Madrid, Spain., Ghanima W; Institute of Clinical Medicine, University of Oslo , Oslo, Norway.; Department of Research, Østfold Hospital Trust , Grålum, Norway.; Department of Medicine, Østfold Hospital Trus , Grålum, Norway., Martinez C; Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Servicio de Hematología y Oncología Médica, Universidad de Murcia , Murcia, Spain., Gonzalez-Conejero R; Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Servicio de Hematología y Oncología Médica, Universidad de Murcia , Murcia, Spain.

المصدر: Platelets [Platelets] 2020 Oct 02; Vol. 31 (7), pp. 906-912. Date of Electronic Publication: 2019 Nov 24.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Informa Healthcare Country of Publication: England NLM ID: 9208117 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1369-1635 (Electronic) Linking ISSN: 09537104 NLM ISO Abbreviation: Platelets Subsets: MEDLINE

مواضيع طبية MeSH: Extracellular Traps/*immunology , Platelet Activation/*immunology , Purpura, Thrombocytopenic, Idiopathic/*drug therapy, Case-Control Studies ; Female ; Humans ; Male ; Middle Aged

المؤلفون: Conteduca V; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Wetterskog D; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK., Sharabiani MTA; Research Data Management and Statistics Unit, The Royal Marsden NHS Foundation Trust, London, UK., Grande E; Department of Medical Oncology, Hospital Ramón y Cajal, Madrid., Fernandez-Perez MP; Department of Hematology & Medical Oncology, Hospital Universitario Morales Meseguer, IMIB-Universidad de Murcia, Murcia., Jayaram A; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.; Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK., Salvi S; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Castellano D; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain., Romanel A; Centre for Integrative Biology, University of Trento, Trento, Italy., Lolli C; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Casadio V; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Gurioli G; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Amadori D; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Font A; Oncology Unit, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona., Vazquez-Estevez S; Department of Medical Oncology, H. Universitario Lucus Augusti, Lugo., González Del Alba A; Department of Medical Oncology, H.U. Son Espases Mallorca, Mallorca., Mellado B; Department of Medical Oncology, IDIBAPS Hospital Clinic, Barcelona., Fernandez-Calvo O; Department of Medical Oncology, Hospital de Orense, Orense., Méndez-Vidal MJ; Department of Medical Oncology, Hospital Universitario Reina Sofía, Córdoba., Climent MA; Department of Medical Oncology, Instituto Valenciano de Oncología Valencia, Valencia., Duran I; Department of Medical Oncology, Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla., Gallardo E; Department of Medical Oncology, H.U. Parc Taulí, Sabadell, Barcelona., Rodriguez A; Department of Medical Oncology, Hospital de León, León., Santander C; Department of Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza., Sáez MI; Department of Medical Oncology, Hospital Regional y Hospital Virgen de la Victoria, Malaga., Puente J; Department of Medical Oncology, Hospital Clínico San Carlos, Madrid, Spain., Gasi Tandefelt D; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK., Wingate A; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK., Dearnaley D; Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK.; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK., Demichelis F; Centre for Integrative Biology, University of Trento, Trento, Italy.; Institute for Precision Medicine, Weill Cornell Medicine, New York, USA., De Giorgi U; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Gonzalez-Billalabeitia E; Department of Hematology & Medical Oncology, Hospital Universitario Morales Meseguer, IMIB-Universidad de Murcia, Murcia.; Department of Medical Oncology, Universidad Católica San Antonio de Murcia-UCAM, Murcia, Spain., Attard G; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.; Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK.

مؤلفون مشاركون: PREMIERE Collaborators, Spanish Oncology Genitourinary Group

المصدر: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2017 Jul 01; Vol. 28 (7), pp. 1508-1516.

نوع المنشور: Clinical Trial; Comparative Study; Journal Article; Multicenter Study

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Androstenes/*therapeutic use , Antineoplastic Agents, Hormonal/*therapeutic use , Biomarkers, Tumor/*blood , Circulating Tumor DNA/*blood , Phenylthiohydantoin/*analogs & derivatives , Prostatic Neoplasms, Castration-Resistant/*blood , Prostatic Neoplasms, Castration-Resistant/*drug therapy , Receptors, Androgen/*blood, Adult ; Aged ; Aged, 80 and over ; Androstenes/adverse effects ; Antineoplastic Agents, Hormonal/adverse effects ; Benzamides ; Biomarkers, Tumor/genetics ; Circulating Tumor DNA/genetics ; DNA Mutational Analysis ; Disease Progression ; Disease-Free Survival ; Europe ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Multiplex Polymerase Chain Reaction ; Multivariate Analysis ; Mutation ; Nitriles ; Odds Ratio ; Patient Selection ; Phenylthiohydantoin/adverse effects ; Phenylthiohydantoin/therapeutic use ; Precision Medicine ; Predictive Value of Tests ; Proportional Hazards Models ; Prospective Studies ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/mortality ; Receptors, Androgen/genetics ; Risk Factors ; Time Factors ; Treatment Outcome